Century Therapeutics Inc (IPSC)

$2.18 +0.05 (2.35%)
Market Cap 186.17M
Revenue (ttm) 6.59M
Net Income (ttm) -126.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,920.64%
Debt to Equity Ratio 0.00
Volume 777,600
Avg Vol 1,957,488
Day's Range N/A - N/A
Shares Out 87.41M
Stochastic %K 73%
Beta 1.75
Analysts Strong Sell
Price Target $4.27

Company Profile

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 817 5790
Address:
25 North 38th Street, 11th Floor, Philadelphia, United States
Jnutz14
Jnutz14 Feb. 26 at 1:52 PM
$IPSC
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 4:34 PM
$IPSC Current Stock Price: $2.24 Contracts to trade: $2.5 IPSC Mar 20 2026 Call Entry: $0.10 Exit: $0.18 ROI: 79% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Invest2live
Invest2live Feb. 25 at 3:35 PM
$IPSC 332% already; checkout $HUMA and $QSI as well as $ARAY. Do your DD and get in.
1 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 25 at 3:01 PM
$IPSC 😮
0 · Reply
notreload_ai
notreload_ai Feb. 25 at 12:11 PM
TD Cowen starts coverage on $IPSC with a Buy rating, highlighting its lead stem cell therapy for type 1 diabetes and potential for long-term value as the pipeline grows. https://notreload.xyz/td-cowen-initiates-buy-on-century-therapeutics-ipsc-strong-diabetes-outlook/
0 · Reply
Jnutz14
Jnutz14 Feb. 25 at 11:52 AM
$IPSC
0 · Reply
LunarPanda1
LunarPanda1 Feb. 24 at 12:53 AM
<>@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $ECO $GPN $IPSC $CHAI *^* on my wl as well
0 · Reply
PandaSwingz
PandaSwingz Feb. 23 at 1:31 PM
$BAND $STRO $EYPT $IPSC {•}•
0 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 19 at 9:43 PM
$IPSC Wonder, why its keep heading upwards momentumly 🤔
0 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 19 at 8:51 PM
$IPSC 👀 no volume but, its .....
0 · Reply
Latest News on IPSC
Century Therapeutics to Participate in Upcoming Investor Conferences in March

Feb 25, 2026, 8:00 AM EST - 1 day ago

Century Therapeutics to Participate in Upcoming Investor Conferences in March

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Feb 16, 2026, 1:00 PM EST - 9 days ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

FATE

Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race

Feb 9, 2026, 11:15 AM EST - 16 days ago

Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:01 PM EST - 3 months ago

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 7:30 AM EST - 3 months ago

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Nov 13, 2025, 7:00 AM EST - 3 months ago

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 4:01 PM EDT - 4 months ago

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 22, 2025, 8:00 AM EDT - 6 months ago

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:01 PM EDT - 6 months ago

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

May 28, 2025, 4:01 PM EDT - 9 months ago

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:01 PM EDT - 10 months ago

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 10 months ago

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 9:05 AM EST - 1 year ago

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Nov 4, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 20, 2024, 11:07 AM EDT - 1 year ago

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 19, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 6:03 PM EST - 2 years ago

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Dec 9, 2023, 12:00 PM EST - 2 years ago

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

Dec 6, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Dec 6, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:01 AM EST - 2 years ago

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Nov 9, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 9, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

Apr 17, 2023, 7:00 AM EDT - 3 years ago

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

Century Therapeutics Announces Leadership Changes

Apr 12, 2023, 8:30 AM EDT - 3 years ago

Century Therapeutics Announces Leadership Changes

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Mar 16, 2023, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Century Therapeutics to Present at the AACR Annual Meeting 2023

Mar 15, 2023, 4:01 PM EDT - 3 years ago

Century Therapeutics to Present at the AACR Annual Meeting 2023

Century Therapeutics to Present at Upcoming Investor Conferences

Feb 21, 2023, 7:00 AM EST - 3 years ago

Century Therapeutics to Present at Upcoming Investor Conferences

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

Feb 8, 2023, 7:30 AM EST - 3 years ago

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 3 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE TECH TAOX

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

Jan 10, 2023, 7:33 AM EST - 3 years ago

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

FATE THRD VERA

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Jan 9, 2023, 9:06 PM EST - 3 years ago

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

Jan 5, 2023, 4:01 PM EST - 3 years ago

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 7:00 AM EST - 3 years ago

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 3 years ago

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Nov 11, 2022, 7:00 AM EST - 3 years ago

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Jnutz14
Jnutz14 Feb. 26 at 1:52 PM
$IPSC
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 4:34 PM
$IPSC Current Stock Price: $2.24 Contracts to trade: $2.5 IPSC Mar 20 2026 Call Entry: $0.10 Exit: $0.18 ROI: 79% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Invest2live
Invest2live Feb. 25 at 3:35 PM
$IPSC 332% already; checkout $HUMA and $QSI as well as $ARAY. Do your DD and get in.
1 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 25 at 3:01 PM
$IPSC 😮
0 · Reply
notreload_ai
notreload_ai Feb. 25 at 12:11 PM
TD Cowen starts coverage on $IPSC with a Buy rating, highlighting its lead stem cell therapy for type 1 diabetes and potential for long-term value as the pipeline grows. https://notreload.xyz/td-cowen-initiates-buy-on-century-therapeutics-ipsc-strong-diabetes-outlook/
0 · Reply
Jnutz14
Jnutz14 Feb. 25 at 11:52 AM
$IPSC
0 · Reply
LunarPanda1
LunarPanda1 Feb. 24 at 12:53 AM
<>@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $ECO $GPN $IPSC $CHAI *^* on my wl as well
0 · Reply
PandaSwingz
PandaSwingz Feb. 23 at 1:31 PM
$BAND $STRO $EYPT $IPSC {•}•
0 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 19 at 9:43 PM
$IPSC Wonder, why its keep heading upwards momentumly 🤔
0 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 19 at 8:51 PM
$IPSC 👀 no volume but, its .....
0 · Reply
Jogozilla
Jogozilla Feb. 19 at 7:18 PM
$3 is inevitable $IPSC
0 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 19 at 4:21 PM
$IPSC
0 · Reply
Gtrading1234
Gtrading1234 Feb. 19 at 2:57 AM
$IPSC
0 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 18 at 5:16 PM
$IPSC 👀
0 · Reply
Jnutz14
Jnutz14 Feb. 18 at 3:22 PM
$IPSC Next phase fda trial results are way overdue here.... Lets see it!
0 · Reply
Jnutz14
Jnutz14 Feb. 18 at 3:19 PM
$IPSC hope you all loaded up.
0 · Reply
CarmelaRamos146
CarmelaRamos146 Feb. 18 at 2:09 PM
$IPSC Oncology biotech with gene-editing focus.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 5:43 PM
$IPSC RSI: 27.61, MACD: 0.0667 Vol: 0.29, MA20: 2.02, MA50: 1.44 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 12 at 5:34 PM
$IPSC Current Stock Price: $1.77 Contracts to trade: $2.0 IPSC Feb 20 2026 Call Entry: $0.02 Exit: $0.03 ROI: 60% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
None_
None_ Feb. 11 at 11:15 PM
$IPSC https://www.fiercebiotech.com/biotech/only-thing-saves-us-data-allogeneic-car-t-biotechs-fight-relevance-industry-moves
0 · Reply
OuiWILLsee
OuiWILLsee Feb. 11 at 9:39 PM
$IPSC are we there yet?
0 · Reply
Beanie_Mojo
Beanie_Mojo Feb. 11 at 4:53 PM
$IPSC Long ways to Go!!
0 · Reply